Suggestions
Michele Oshman
Vice President for External Affairs at Biotechnology Innovation Organization
Professional Background
Michele M. Oshman is an exceptionally experienced and dynamic leader within the biotechnology industry, showcasing a robust history of engaging with patients, professional groups, and trade associations to positively impact health outcomes and policy reform. With extensive experience in advocating for patient access and navigating complex market dynamics, Michele has established herself as a reputable and credible voice for patients, especially in the areas of federal healthcare policies, such as Medicare, Medicaid, and the Prescription Drug User Fee Act (PDUFA).
Throughout her professional journey, Michele has cultivated a deep understanding of significant disease areas, including lupus, psoriasis, arthritis, psychiatry, neurodegeneration, pain, and osteoporosis. Her commitment to advocating for patients' interests and facilitating stakeholder collaborations distinguishes her leadership in the sector.
Education and Achievements
Michele's academic background includes a Bachelor of Arts (B.A.) in Political Science with a focus on Public Policy from American University, where she developed strong analytical skills and a solid foundation in the intersection of politics and healthcare. This education has been instrumental in her career, allowing her to navigate complex healthcare landscapes effectively. Although she also studied Pre-Pharmacy and Pharmacy at the University of Maryland School of Pharmacy, her primary focus and impactful contributions have been in public policy and patient advocacy.
Michele's career has spanned several significant roles at Eli Lilly and Company, one of the world’s leading pharmaceutical firms. She has thrived in various positions, including Director of Federal Advocacy and Alliance Development, Director of Global Advocacy and Professional Relations, and Director of U.S. Neurosciences - Advocacy and Professional Relations. Each of these roles has permitted her to hone her skills in advocacy, strategy development, and stakeholder engagement, facilitating Eli Lilly's efforts to navigate intricate regulatory ecosystems effectively. Furthermore, as a Six Sigma Black Belt, Michele combines strategic thinking with operational excellence that leads to improved processes and enhanced outcomes.
Notable Achievements
Michele has not only been an advocate within her company but also played a pivotal role in the broader biotechnology field through her position as Vice President for External Affairs at the Biotechnology Innovation Organization (BIO). In this capacity, she influences policy decisions that benefit patients and enhances the biotechnology landscape. Her ability to communicate effectively with various stakeholders, including government entities, patient advocacy groups, and healthcare professionals, has established her as a thought leader in the industry.
An exceptional aspect of Michele's career is her commitment to remaining at the forefront of evolving healthcare policies and practices. Her expertise in federal healthcare policy and multiple disease areas equips her to drive meaningful dialogue surrounding drug access, assessment, and intellectual property. This combination of experience, passion, and ethical leadership continues to solidify her reputation as an indispensable leader in biotechnology and patient advocacy.
Overall, Michele M. Oshman exemplifies dedication, expertise, and leadership in the biotechnology industry. Her substantial background equips her to navigate complex healthcare challenges where patient needs remain the priority, and her work positively influences professionals and patients alike.
